ReportsHIV

A randomized controlled safety/efficacy trial of therapeutic vaccination in HIV-infected individuals who initiated antiretroviral therapy early in infection

See allHide authors and affiliations

Science Translational Medicine  06 Dec 2017:
Vol. 9, Issue 419, eaan8848
DOI: 10.1126/scitranslmed.aan8848

Article Information

vol. 9 no. 419

PubMed: 
Print ISSN: 
Online ISSN: 
History: 
  • Received for publication June 21, 2017
  • Accepted for publication October 13, 2017

Author Information

  1. Michael C. Sneller1,
  2. J. Shawn Justement1,
  3. Kathleen R. Gittens2,
  4. Mary E. Petrone1,
  5. Katherine E. Clarridge1,
  6. Michael A. Proschan3,
  7. Richard Kwan2,
  8. Victoria Shi1,
  9. Jana Blazkova1,
  10. Eric W. Refsland1,
  11. Daryl E. Morris4,
  12. Kristen W. Cohen4,
  13. M. Juliana McElrath4,5,
  14. Rong Xu6,
  15. Michael A. Egan6,
  16. John H. Eldridge6,
  17. Erika Benko7,
  18. Colin Kovacs7,8,
  19. Susan Moir1,
  20. Tae-Wook Chun1,*, and
  21. Anthony S. Fauci1,*
  1. 1Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD 20892, USA.
  2. 2Critical Care Medicine Department, Clinical Center, NIH, Bethesda, MD 20892, USA.
  3. 3Biostatistics Research Branch, NIAID, NIH, Bethesda, MD 20892, USA.
  4. 4Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
  5. 5Department of Global Health, University of Washington, Seattle, WA 98195, USA.
  6. 6Profectus BioSciences Inc., Tarrytown, NY 10591, USA.
  7. 7Maple Leaf Medical Clinic, Toronto, Ontario M5G 1K2, Canada.
  8. 8Department of Medicine, University of Toronto, Toronto, Ontario M5S 1A1, Canada.
  1. Corresponding author. Email: twchun{at}nih.gov
    • * These authors contributed equally to this work.

    Altmetric

    Article usage

    Article usage: December 2017 to December 2017

    AbstractFullPdf
    Dec 20173796536821